| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006736954 |
| P356 | DOI | 10.2165/00002018-199920020-00004 |
| P698 | PubMed publication ID | 10082071 |
| P2093 | author name string | P Vermeij | |
| W Meinhardt | |||
| R F Kropman | |||
| P2860 | cites work | Oral phentolamine as treatment for erectile dysfunction | Q74328610 |
| Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents | Q74384463 | ||
| Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study | Q74738450 | ||
| Acute myocardial infarction associated with sildenafil | Q77347409 | ||
| Suppression of prostaglandin E1-induced pain by dilution of the drug with lidocaine before intracavernous injection | Q28316807 | ||
| An Improved Vasoactive Drug Combination for a Pharmacological Erection Program | Q28324132 | ||
| Non-invasive Management of Impotence with Transcutaneous Nitroglycerin | Q28324563 | ||
| Minoxidil versus nitroglycerin: a prospective double-blind controlled trial in transcutaneous erection facilitation for organic impotence | Q28333342 | ||
| Intracavernous injection therapy: analysis of results and complications | Q28335044 | ||
| Dose-dependent effect and side-effect of prostaglandin E1 in erectile dysfunction | Q28355562 | ||
| Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction | Q33175472 | ||
| Priapism induced by chlorpromazine and trazodone: mechanism of action | Q34050234 | ||
| Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group | Q34732756 | ||
| Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline | Q34750117 | ||
| Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function | Q36457086 | ||
| Self-administration in the pharmacological treatment of impotence | Q37917098 | ||
| Long-term follow-up of patients receiving injection therapy for erectile dysfunction | Q38557543 | ||
| A ten-year safety study of the oral androgen testosterone undecanoate. | Q39389223 | ||
| Abnormalities of ejaculation | Q39510939 | ||
| Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor | Q40092671 | ||
| Physiology of penile erection | Q40576740 | ||
| Prosexual drugs: empirical status of the "new aphrodisiacs". | Q40619871 | ||
| The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience | Q40949530 | ||
| Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission | Q41082098 | ||
| Impotence responsive to glyceryl trinitrate | Q41277570 | ||
| Endothelial dysfunction and hypertension. | Q41349623 | ||
| Inhibition of nerve stimulation‐induced vasodilatation in corpora cavernosa of the pithed rat by blockade of nitric oxide synthase | Q41896468 | ||
| Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence | Q42202810 | ||
| Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections. | Q42278585 | ||
| Intracavernous injection of prostaglandin E1 plus procaine in the treatment of erectile dysfunction | Q42284074 | ||
| Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction | Q42288859 | ||
| Alkalization does not alleviate penile pain induced by intracavernous injection of prostaglandin E1. | Q42555292 | ||
| Slow injection of prostaglandin E1 decreases associated penile pain | Q42555718 | ||
| Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction | Q42679993 | ||
| Assessment of erectogenic properties of apomorphine and yohimbine in man. | Q43229303 | ||
| Improved hemodynamic response after long-term intracavernous injection for impotence | Q43449170 | ||
| Hemodynamics of papaverine- and phentolamine-induced penile erection | Q43672927 | ||
| Increased libido in three men treated with trazodone | Q44771679 | ||
| Prostaglandin E1 therapy for impotence, comparison with papaverine | Q44943417 | ||
| Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure | Q45095902 | ||
| The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection. | Q45976859 | ||
| Double-blind trial of yohimbine in treatment of psychogenic impotence. | Q45979285 | ||
| Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial | Q46334433 | ||
| Intracavernous injection of linsidomine chlorhydrate in monkeys: lack of toxic effect with long-term use. | Q46732089 | ||
| Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group | Q46895448 | ||
| Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat. | Q48578317 | ||
| Pathophysiology of prolonged penile erection associated with trazodone use. | Q48912377 | ||
| Enhancement of sexual motivation in male rats by yohimbine | Q49011465 | ||
| Influence of the method of intracavernous injection on penile rigidity: a possible pharmacokinetic explanation | Q49095952 | ||
| Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study. | Q50959342 | ||
| Clomipramine and sexual function in men with premature ejaculation and controls. | Q51009639 | ||
| Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose-response study. | Q51104752 | ||
| Endothelin-1 as a putative modulator of erectile dysfunction: I. Characteristics of contraction of isolated corporal tissue strips. | Q52339584 | ||
| Concepts in risk-benefit assessment. A simple merit analysis of a medicine? | Q53621024 | ||
| INTRACAVERNOSAL FORSKOLIN: ROLE IN MANAGEMENT OF VASCULOGENIC IMPOTENCE RESISTANT TO STANDARD 3-AGENT PHARMACOTHERAPY | Q57576201 | ||
| YOHIMBINE FOR ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS | Q57942829 | ||
| Effect of yohimbine-trazodone on psychogenic impotence: A randomized, double-blind, placebo-controlled study | Q60626553 | ||
| Four-Drug Intracavernous Therapy for Impotence Due to Corporeal Veno-Occlusive Dysfunction | Q60626557 | ||
| Nitric oxide: a physiologic mediator of penile erection | Q67539737 | ||
| Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial | Q68156062 | ||
| Intracavernous Self-Injection of Vasoactive Drugs in the Treatment of Impotence: 8-Year Experience with 615 Cases | Q68290980 | ||
| Intracavernous injection of prostaglandin E1 in impotent men | Q68394781 | ||
| Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence | Q69380429 | ||
| A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence | Q69486073 | ||
| Effect of yohimbine hydrochloride on erectile impotence: a double-blind study | Q69503763 | ||
| Increased libido in women receiving trazodone | Q69535912 | ||
| The pH analysis of papaverine-phentolamine and prostaglandin E1 for pharmacologic erection | Q69615562 | ||
| Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery | Q69914301 | ||
| Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence | Q69940072 | ||
| Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison | Q69949332 | ||
| Oral and transcutaneous pharmacologic agents in the treatment of impotence | Q70378129 | ||
| Efficiency and side effects of intracavernous injections of moxisylyte in impotent patients: a dose-finding study versus placebo | Q70544066 | ||
| Testosterone is required for the stimulatory effects of 8-OH-DPAT on sexual behavior in castrated male rats | Q70647300 | ||
| An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation | Q70659017 | ||
| Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction | Q70672783 | ||
| Pharmacological management of erectile dysfunction | Q70787766 | ||
| Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate | Q70809074 | ||
| Pharmacokinetics of moxisylyte in healthy volunteers after intravenous infusion and intracavernous administration with and without a penile tourniquet | Q71295876 | ||
| Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction | Q71334813 | ||
| Sildenafil, a novel effective oral therapy for male erectile dysfunction | Q71547678 | ||
| A randomized crossover study using yohimbine and isoxsuprine versus pentoxifylline in the management of vasculogenic impotence | Q71566642 | ||
| The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study | Q71667740 | ||
| Trial of pentoxifylline for diabetic impotence | Q71733408 | ||
| A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group | Q71752213 | ||
| Response of the urethral and intracorporeal pressures to cavernosus muscle stimulation: Role of the muscles in erection and ejaculation | Q71855979 | ||
| A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil | Q71917558 | ||
| Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction | Q72033773 | ||
| Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction | Q72091775 | ||
| Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study | Q72144495 | ||
| Fluoxetine for premature ejaculation | Q72205019 | ||
| Pharmacokinetics of moxisylyte in healthy volunteers after intravenous and intracavernous administration | Q72230208 | ||
| Retrograde ejaculation and loss of emission: possibilities of conservative treatment | Q72498990 | ||
| Recovery of erectile function by the oral administration of apomorphine | Q72545313 | ||
| PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle | Q72558622 | ||
| Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction | Q72756315 | ||
| Effects of castration and exogenous testosterone supplementation in an animal model of penile erection | Q72775255 | ||
| Functional and radiologic evidence of vascular communication between the spongiosal and cavernosal compartments of the penis | Q73328647 | ||
| Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro | Q73457349 | ||
| Trazodone, a double blind trial for treatment of erectile dysfunction | Q73744302 | ||
| Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction | Q73944595 | ||
| Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction | Q74089990 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 133-146 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Comparative tolerability and efficacy of treatments for impotence | |
| P478 | volume | 20 |
| Q44257739 | A novel compound JPM8: in vivo penile activity promotion in rats, effect on the relaxation and cGMP/cAMP accumulation in isolated rabbit corpora cavernosa |
| Q43700463 | Dual mechanism of action of nicorandil on rabbit corpus cavernosal smooth muscle tone |
| Q34636215 | Evaluation of the aphrodisiac activity of Tribulus terrestris Linn. in sexually sluggish male albino rats |
| Q28140656 | Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function |
| Q34385713 | Pathophysiology and diagnosis of male erectile dysfunction |
| Q44762862 | Possible hemodynamic pathways of intraurethral prostaglandin-E1 (MUSE). |
| Q43732316 | Short-term histopathologic effects of different intracavernosal agents on corpus cavernosum and antifibrotic activity of intracavernosal verapamil: an experimental study |
Search more.